Search

Your search keyword '"Baciarello, Giulia"' showing total 159 results
Start Over Author "Baciarello, Giulia"
159 results on '"Baciarello, Giulia"'

1. Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

Author

Danlos, François-Xavier, Grajeda-Iglesias, Claudia, Durand, Sylvère, Sauvat, Allan, Roumier, Mathilde, Cantin, Delphine, Colomba, Emeline, Rohmer, Julien, Pommeret, Fanny, Baciarello, Giulia, Willekens, Christophe, Vasse, Marc, Griscelli, Frank, Fahrner, Jean-Eudes, Goubet, Anne-Gaëlle, Dubuisson, Agathe, Derosa, Lisa, Nirmalathasan, Nitharsshini, Bredel, Delphine, Mouraud, Séverine, Pradon, Caroline, Stoclin, Annabelle, Rozenberg, Flore, Duchemin, Jérôme, Jourdi, Georges, Ellouze, Syrine, Levavasseur, Françoise, Albigès, Laurence, Soria, Jean-Charles, Barlesi, Fabrice, Solary, Eric, André, Fabrice, Pène, Frédéric, Ackerman, Félix, Mouthon, Luc, Zitvogel, Laurence, Marabelle, Aurélien, Michot, Jean-Marie, Fontenay, Michaela, and Kroemer, Guido

Published
2024
Full Text
View/download PDF

2. Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial

Author

Baciarello, Giulia, Delva, Remy, Gravis, Gwenaelle, Tazi, Youssef, Beuzeboc, Philippe, Gross-Goupil, Marine, Bompas, Emmanuelle, Joly, Florence, Greilsamer, Charlotte, Hon, Thierry Nguyen Tan, Barthelemy, Philippe, Culine, Stephane, Berdah, Jean Francois, Deblock, Mathilde, Ratta, Raffaele, Flechon, Aude, Cheneau, Caroline, Maillard, Aline, Martineau, Geraldine, Borget, Isabelle, and Fizazi, Karim

Published
2022
Full Text
View/download PDF

4. Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects

Author

Aldea, Mihaela, Lam, Laurent, Orillard, Emeline, Llacer Perez, Casilda, Saint-Ghislain, Mathilde, Gravis, Gwenaelle, Fléchon, Aude, Roubaud, Guilhem, Barthelemy, Philippe, Ricci, Francesco, Priou, Frank, Neviere, Zoe, Beaufils, Mathilde, Laguerre, Brigitte, Hardy, Anne-Claire, Helissey, Carole, Ratta, Raffaele, Borchiellini, Delphine, Pobel, Cedric, Joly, Florence, Castro, Elena, Thiery-Vuillemin, Antoine, Baciarello, Giulia, and Fizazi, Karim

Published
2021
Full Text
View/download PDF

10. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

Author

Albiges, Laurence, Foulon, Stéphanie, Bayle, Arnaud, Gachot, Bertrand, Pommeret, Fanny, Willekens, Christophe, Stoclin, Annabelle, Merad, Mansouria, Griscelli, Frank, Lacroix, Ludovic, Netzer, Florence, Hueso, Thomas, Balleyguier, Corinne, Ammari, Samy, Colomba, Emeline, Baciarello, Giulia, Perret, Audrey, Hollebecque, Antoine, Hadoux, Julien, Michot, Jean-Marie, Chaput, Nathalie, Saada, Veronique, Hauchecorne, Mathilde, Micol, Jean-Baptiste, Sun, Roger, Valteau-Couanet, Dominique, André, Fabrice, Scotte, Florian, Besse, Benjamin, Soria, Jean-Charles, and Barlesi, Fabrice

Published
2020
Full Text
View/download PDF

12. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database

Author

Delanoy, Nicolas, Hardy-Bessard, Anne-Claire, Efstathiou, Eleni, Le Moulec, Sylvestre, Basso, Umberto, Birtle, Alison, Thomson, Alastair, Krainer, Michael, Guillot, Aline, De Giorgi, Ugo, Hasbini, Ali, Daugaard, Gedske, Bahl, Amit, Chowdhury, Simon, Caffo, Orazio, Beuzeboc, Philippe, Spaeth, Dominique, Eymard, Jean-Christophe, Fléchon, Aude, Alexandre, Jérôme, Helissey, Carole, Butt, Mohamed, Priou, Frank, Lechevallier, Éric, Deville, Jean-Laurent, Goupil, Marine Gross, Morales, Rafael, Thiery-Vuillemin, Antoine, Gavrikova, Tatiana, Barthelemy, Philippe, Sella, Avishay, Fizazi, Karim, Baciarello, Giulia, Fererro, Jean-Marc, Laguerre, Brigitte, Verret, Benjamin, Hans, Sophie, and Oudard, Stéphane

Published
2018
Full Text
View/download PDF

13. Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer

Author

Thibault, Constance, Eymard, Jean-Christophe, Birtle, Alison, Krainer, Michael, Baciarello, Giulia, Fléchon, Aude, Le Moulec, Sylvestre, Spaeth, Dominique, Laguerre, Brigitte, Caffo, Orazio, Deville, Jean-Laurent, Beuzeboc, Phillipe, Hasbini, Ali, Gross-Goupil, Marine, Helissey, Carole, Bennamoun, Mostefa, Hardy-Bessard, Anne-Claire, and Oudard, Stéphane

Published
2018
Full Text
View/download PDF

14. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

Author

Danlos, François-Xavier, Grajeda-Iglesias, Claudia, Durand, Sylvère, Sauvat, Allan, Roumier, Mathilde, Cantin, Delphine, Colomba, Emeline, Rohmer, Julien, Pommeret, Fanny, Baciarello, Giulia, Willekens, Christophe, Vasse, Marc, Griscelli, Frank, Fahrner, Jean-Eudes, Goubet, Anne-Gaëlle, Dubuisson, Agathe, Derosa, Lisa, Nirmalathasan, Nitharsshini, Bredel, Delphine, Mouraud, Séverine, Pradon, Caroline, Stoclin, Annabelle, Rozenberg, Flore, Duchemin, Jérôme, Jourdi, Georges, Ellouze, Syrine, Levavasseur, Françoise, Albigès, Laurence, Soria, Jean-Charles, Barlesi, Fabrice, Solary, Eric, André, Fabrice, Pène, Frédéric, Ackerman, Félix, Mouthon, Luc, Zitvogel, Laurence, Marabelle, Aurélien, Michot, Jean-Marie, Fontenay, Michaela, and Kroemer, Guido

Published
2021
Full Text
View/download PDF

19. Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma

Author

Parent, Pauline, primary, Auclin, Edouard, additional, Patrikidou, Anna, additional, Mezquita, Laura, additional, Martínez Chanzá, Nieves, additional, Dumont, Clément, additional, Rodriguez-Vida, Alejo, additional, Llacer, Casilda, additional, Lozano, Rebeca, additional, Ratta, Raffaele, additional, Merseburger, Axel S., additional, Sternberg, Cora N., additional, Baciarello, Giulia, additional, Colomba, Emeline, additional, Fuerea, Alina, additional, Besse, Benjamin, additional, Loriot, Yohann, additional, and Lavaud, Pernelle, additional

Published
2023
Full Text
View/download PDF

20. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy

Author

Terbuch, Angelika, primary, Posch, Florian, additional, Bauernhofer, Thomas, additional, Jost, Philipp J., additional, Partl, Richard, additional, Stranzl-Lawatsch, Heidi, additional, Baciarello, Giulia, additional, Fizazi, Karim, additional, Giannatempo, Patrizia, additional, Verzoni, Elena, additional, Sweeney, Christopher, additional, Ravi, Praful, additional, Tran, Ben, additional, Basso, Umberto, additional, White, Jeff, additional, Vincenzi, Bruno, additional, Oing, Christoph, additional, Cutuli, Hernan Javier, additional, Dieckmann, Klaus Peter, additional, Gamulin, Marija, additional, Chovanec, Michal, additional, Fankhauser, Christian Daniel, additional, Heidenreich, Axel, additional, Mohamad, Osama, additional, Thibault, Constance, additional, Fischer, Stefanie, additional, and Gillessen, Silke, additional

Published
2022
Full Text
View/download PDF

21. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy

Author

Terbuch, Angelika, Posch, Florian, Bauernhofer, Thomas, Jost, Philipp J., Partl, Richard, Stranzl-Lawatsch, Heidi, Baciarello, Giulia, Fizazi, Karim, Giannatempo, Patrizia, Verzoni, Elena, Sweeney, Christopher, Ravi, Praful, Tran, Ben, Basso, Umberto, White, Jeff, Vincenzi, Bruno, Oing, Christoph, Cutuli, Hernan Javier, Dieckmann, Klaus Peter, Gamulin, Marija, Chovanec, Michal, Fankhauser, Christian Daniel, Heidenreich, Axel, Mohamad, Osama, Thibault, Constance, Fischer, Stefanie, Gillessen, Silke, Terbuch, Angelika, Posch, Florian, Bauernhofer, Thomas, Jost, Philipp J., Partl, Richard, Stranzl-Lawatsch, Heidi, Baciarello, Giulia, Fizazi, Karim, Giannatempo, Patrizia, Verzoni, Elena, Sweeney, Christopher, Ravi, Praful, Tran, Ben, Basso, Umberto, White, Jeff, Vincenzi, Bruno, Oing, Christoph, Cutuli, Hernan Javier, Dieckmann, Klaus Peter, Gamulin, Marija, Chovanec, Michal, Fankhauser, Christian Daniel, Heidenreich, Axel, Mohamad, Osama, Thibault, Constance, Fischer, Stefanie, and Gillessen, Silke

Abstract

Purpose: Radiation therapy is a possible treatment strategy for patients with testicular seminoma after orchiectomy in clinical stage I or II disease. Little is known about the outcome of patients who experience a relapse after radiation therapy. Methods and Materials: Data from 61 patients who relapsed after adjuvant or curative radiation therapy from 17 centers in 11 countries were collected and retrospectively analyzed. Primary outcomes were disease-free and overall survival. Secondary outcomes were time to relapse, stage at relapse, treatment for relapse, and rate of febrile neutropenia during chemotherapy for relapse. Results: With a median follow-up of 9.9 years (95% confidence interval [CI], 7.5-10.9), we found a 5-year disease-free survival of 90% (95% CI, 79-95) and a 5-year overall survival of 98% (95% CI, 89-100). Sixty-six percent of patients had stage III disease at time of relapse and 93% of patients fell into the good prognosis group per the International Germ Cell Cancer Collaborative Group classification. The median time to relapse after radiation therapy was 15.6 months (95% CI, 12-23). Twenty-two (36%) patients relapsed more than 2 years after radiation therapy and 7 (11.5%) patients relapsed more than 5 years after radiation therapy. One-third of relapses was detected owing to patients' symptoms, whereas two-thirds of relapses were detected during routine follow-up. The majority (93%) of cases were treated with cisplatin-based chemotherapy. The rate of febrile neutropenia during chemotherapy was 35%. Five patients experienced a second relapse. At last follow-up, 55 patients (90%) were alive without disease. Only 1 patient died owing to disease progression. Conclusions: Cisplatin-based chemotherapy for patients with seminoma who have relapsed after treatment with radiation therapy alone leads to excellent outcomes. Patients and physicians should be aware of possible late relapses after radiation therapy. (c) 2022 The Authors. Published by Elsevier

Published
2022

22. Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study

Author

Baciarello, Giulia, primary, Özgüroğlu, Mustafa, additional, Mundle, Suneel, additional, Leitz, Gerhard, additional, Richarz, Ute, additional, Hu, Peter, additional, Feyerabend, Susan, additional, Matsubara, Nobuaki, additional, Chi, Kim N., additional, and Fizazi, Karim, additional

Published
2022
Full Text
View/download PDF

23. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience

Author

Pauli, Chantal, Bochtler, Tilmann, Mileshkin, Linda, Baciarello, Giulia, Losa, Ferran, Ross, Jeffrey S, Pentheroudakis, George, Zarkavelis, George, Yalcin, Suayib, Özgüroğlu, Mustafa, Beringer, Andreas, Scarato, Jeremy, Mueller-Ohldach, Mathis, Thomas, Marlene, Moch, Holger, Krämer, Alwin, University of Zurich, and Pauli, Chantal

Subjects
10049 Institute of Pathology and Molecular Pathology, 610 Medicine & health, 2730 Oncology, 1306 Cancer Research
Published
2021
Full Text
View/download PDF

24. Abstract 358: A prospective study of prostate cancer metastases identifies an androgen receptor activity-low, stemness program associated with resistance to androgen receptor axis inhibitors and unveils mechanisms of clonal evolution

Author

Menssouri, Naoual, primary, Poiraudeau, Loic, additional, Helissey, Carole, additional, Bigot, Ludovic, additional, Sabio, Jonathan, additional, Ibrahim, Tony, additional, Nicotra, Claudio, additional, Ngocamus, Maud, additional, Tselikas, Lambros, additional, De Baere, Thierry, additional, Rouleau, Etienne, additional, Lacroix, Ludovic, additional, Chaucherau, Anne, additional, Friboulet, Luc, additional, Flippot, Ronan, additional, Baciarello, Giulia, additional, Albiges, Laurence, additional, Colomba, Emeline, additional, Lavaud, Pernelle, additional, Michiels, Stefan, additional, Maillard, Aline, additional, Italiano, Antoine, additional, Barlesi, Fabrice, additional, Soria, Jean-Charles, additional, Scoazec, Jean-Yves, additional, Massard, christophe, additional, Besse, Benjamin, additional, André, Fabrice, additional, Fizazi, Karim, additional, Gautheret, Daniel, additional, and Loriot, Yohann, additional

Published
2021
Full Text
View/download PDF

25. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience

Author

Pauli, Chantal; https://orcid.org/0000-0001-9621-8511, Bochtler, Tilmann, Mileshkin, Linda, Baciarello, Giulia, Losa, Ferran, Ross, Jeffrey S, Pentheroudakis, George, Zarkavelis, George, Yalcin, Suayib, Özgüroğlu, Mustafa, Beringer, Andreas, Scarato, Jeremy, Mueller-Ohldach, Mathis, Thomas, Marlene, Moch, Holger, Krämer, Alwin, Pauli, Chantal; https://orcid.org/0000-0001-9621-8511, Bochtler, Tilmann, Mileshkin, Linda, Baciarello, Giulia, Losa, Ferran, Ross, Jeffrey S, Pentheroudakis, George, Zarkavelis, George, Yalcin, Suayib, Özgüroğlu, Mustafa, Beringer, Andreas, Scarato, Jeremy, Mueller-Ohldach, Mathis, Thomas, Marlene, Moch, Holger, and Krämer, Alwin

Abstract

BACKGROUND CUPISCO is an ongoing randomized phase II trial (NCT03498521) comparing molecularly guided therapy versus platinum-based chemotherapy in patients newly diagnosed with "unfavorable" cancer of unknown primary (CUP). MATERIALS AND METHODS Patients with an unfavorable CUP diagnosis, as defined by the European Society of Medical Oncology (ESMO), and available cancer tissue for molecular sequencing are generally eligible. Potential patients with CUP entering screening undergo a review involving reference histopathology and clinical work-up by a central eligibility review team (ERT). Patients with "favorable" CUP, a strongly suspected primary site of origin, lack of tissue, or unmet inclusion criteria are excluded. RESULTS As of April 30, 2020, 628 patients had entered screening and 346 (55.1%) were screen failed. Screen fails were due to technical reasons (n = 89), failure to meet inclusion and exclusion criteria not directly related to CUP diagnosis (n = 89), and other reasons (n = 33). A total of 124 (35.8%) patients were excluded because unfavorable adeno- or poorly differentiated CUP could not be confirmed by the ERT. These cases were classified into three groups ineligible because of (a) histologic subtype, such as squamous and neuroendocrine, or favorable CUP; (b) evidence of a possible primary tumor; or (c) noncarcinoma histology. CONCLUSION Experience with CUPISCO has highlighted challenges with standardized screening in an international clinical trial and the difficulties in diagnosing unfavorable CUP. Reconfirmation of unfavorable CUP by an ERT in a clinical trial can result in many reasons for screen failures. By sharing this experience, we aim to foster understanding of diagnostic challenges and improve diagnostic pathology and clinical CUP algorithms. IMPLICATIONS FOR PRACTICE A high unmet need exists for improved treatment of cancer of unknown primary (CUP); however, study in a trial setting is faced with the significant challenge of definitively

Published
2021

26. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design

Author

Ross, Jeffrey S; https://orcid.org/0000-0001-8494-2596, Sokol, Ethan S; https://orcid.org/0000-0002-2988-0537, Moch, Holger; https://orcid.org/0000-0002-7986-2839, Mileshkin, Linda; https://orcid.org/0000-0001-6826-6014, Baciarello, Giulia; https://orcid.org/0000-0002-5396-5071, Losa, Ferran; https://orcid.org/0000-0003-4355-6626, Beringer, Andreas; https://orcid.org/0000-0002-3893-8606, Thomas, Marlene, Elvin, Julia; https://orcid.org/0000-0001-9476-9563, Ngo, Nhu; https://orcid.org/0000-0002-0719-0797, Jin, Dexter X; https://orcid.org/0000-0003-1533-6730, Krämer, Alwin, Ross, Jeffrey S; https://orcid.org/0000-0001-8494-2596, Sokol, Ethan S; https://orcid.org/0000-0002-2988-0537, Moch, Holger; https://orcid.org/0000-0002-7986-2839, Mileshkin, Linda; https://orcid.org/0000-0001-6826-6014, Baciarello, Giulia; https://orcid.org/0000-0002-5396-5071, Losa, Ferran; https://orcid.org/0000-0003-4355-6626, Beringer, Andreas; https://orcid.org/0000-0002-3893-8606, Thomas, Marlene, Elvin, Julia; https://orcid.org/0000-0001-9476-9563, Ngo, Nhu; https://orcid.org/0000-0002-0719-0797, Jin, Dexter X; https://orcid.org/0000-0003-1533-6730, and Krämer, Alwin

Abstract

BACKGROUND Carcinoma of unknown primary origin (CUP) accounts for 2%-5% of newly diagnosed advanced malignancies, with chemotherapy as the standard of care. CUPISCO (NCT03498521) is an ongoing randomized trial using comprehensive genomic profiling (CGP) to assign patients with CUP to targeted or immunotherapy treatment arms based on genomic profiling. We performed a retrospective analysis of CUP cases referred for CGP to determine how many were potentially eligible for enrollment into an experimental CUPISCO arm. MATERIALS AND METHODS Centrally reviewed adenocarcinoma and undifferentiated CUP specimens in the FoundationCore database were analyzed using the hybrid capture-based FoundationOne CDx assay (mean coverage, >600×). Presence of genomic alterations, microsatellite instability (MSI), tumor mutational burden (TMB), genomic loss of heterozygosity (gLOH), and programmed death-ligand 1 (PD-L1) positivity were determined. RESULTS A total of 96 of 303 patients (31.7%) could be matched to an experimental CUPISCO arm. Key genomic alterations included ERBB2 (7.3%), PIK3CA (6.3%), NF1 (5.6%), NF2 (4.6%), BRAF (4.3%), IDH1 (3.3%), PTEN, FGFR2, EGFR (3.6% each), MET (4.3%), CDK6 (3.0%), FBXW7, CDK4 (2.3% each), IDH2, RET, ROS1, NTRK (1.0% each), and ALK (0.7%). Median TMB was 3.75 mutations per megabyte of DNA; 34 patients (11.6%) had a TMB greater or equal to 16 mutations per megabyte. Three patients (1%) had high MSI, and 42 (14%) displayed high PD-L1 expression (tumor proportion score ≥50%). gLOH could be assessed in 199 or 303 specimens; 19.6% had a score of >16%. CONCLUSIONS Thirty-two percent of patients would have been eligible for targeted therapy in CUPISCO. Future studies, including additional biomarkers such as PD-L1 positivity and gLOH, may identify a greater proportion potentially benefiting from CGP-informed treatment. Clinical trial identification number. NCT03498521 IMPLICATIONS FOR PRACTICE: The findings of this retrospective analysis of carcinoma of unkn

Published
2021

27. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience

Author

Pauli, Chantal, primary, Bochtler, Tilmann, additional, Mileshkin, Linda, additional, Baciarello, Giulia, additional, Losa, Ferran, additional, Ross, Jeffrey S., additional, Pentheroudakis, George, additional, Zarkavelis, George, additional, Yalcin, Suayib, additional, Özgüroğlu, Mustafa, additional, Beringer, Andreas, additional, Scarato, Jeremy, additional, Mueller-Ohldach, Mathis, additional, Thomas, Marlene, additional, Moch, Holger, additional, and Krämer, Alwin, additional

Published
2021
Full Text
View/download PDF

31. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design

Author

Ross, Jeffrey S., primary, Sokol, Ethan S., additional, Moch, Holger, additional, Mileshkin, Linda, additional, Baciarello, Giulia, additional, Losa, Ferran, additional, Beringer, Andreas, additional, Thomas, Marlene, additional, Elvin, Julia A., additional, Ngo, Nhu, additional, Jin, Dexter X., additional, and Krämer, Alwin, additional

Published
2020
Full Text
View/download PDF

33. Biomarker-driven immunotherapy for precision medicine in prostate cancer.

Author

Ottini, Arianna, Sepe, Pierangela, Beninato, Teresa, Claps, Mélanie, Guadalupi, Valentina, Verzoni, Elena, Giannatempo, Patrizia, Baciarello, Giulia, de Braud, Filippo, and Procopio, Giuseppe

Abstract

Although immunotherapy has recently revolutionized standard of care in different cancer types, prostate cancer has generally failed to show dramatic responses to immune checkpoint inhibitors. As in other tumors, the goal in prostate cancer is now to target treatments more precisely on patient's individual characteristics through precision medicine. Defects in mismatch repair, mutations in the exonuclease domain of the DNA polymerase epsilon (POLE), high tumor mutational burden and the presence of biallelic loss of CDK12 among others, are predictive biomarkers of response to immunotherapy. In the present review, we summarize the evolving landscape of immunotherapy in prostate cancer, including precision approaches and strategies to define classes of responsive patients and scale up resistance to immune checkpoint inhibitors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Association of the Lung Immune Prognostic Index with outcome in patients with metastatic urothelial cancer treated with immune checkpoint inhibitor.

Author

Pauline, Parent, primary, Auclin, Edouard, additional, Mezquita, Laura, additional, Chanza, Nieves M., additional, Dumont, Clement, additional, Rodriguez-Vida, Alejo, additional, Lozano, Rebeca, additional, Vera, Beatriz, additional, Ratta, Raffaele, additional, Baciarello, Giulia, additional, Colomba, Emeline, additional, Fuerea, Alina, additional, Besse, Benjamin, additional, Loriot, Yohann, additional, and Lavaud, Pernelle, additional

Published
2020
Full Text
View/download PDF

35. Semi-ResMass Study: Residual masses after salvage chemotherapy in men with pure seminoma—A multicenter retrospective analysis.

Author

Baciarello, Giulia, primary, Brard, Caroline, additional, Aldea, Mihaela, additional, Oing, Christoph, additional, De Giorgi, Ugo, additional, Morelli, Franco, additional, Pouessel, Damien, additional, Secondino, Simona, additional, Vincenzi, Bruno, additional, Tardy, Magalie Pascale, additional, Crouzet, Laurence, additional, Ladoire, Sylvain, additional, Foulon, Stéphanie, additional, and Fizazi, Karim, additional

Published
2020
Full Text
View/download PDF

38. Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).

Author

Baciarello, Giulia, primary, Delva, Remy, additional, Gravis, Gwenaelle, additional, Tazi, Youssef, additional, Theodore, Christine, additional, Gross-Goupil, Marine, additional, Bompas, Emmanuelle, additional, Joly, Florence, additional, Lharidon, Tifenn, additional, Nguyen Tan Hon, Thierry, additional, Barthelemy, Philippe, additional, Culine, Stephane, additional, Berdah, Jean Francois, additional, Deblock, Mathilde, additional, Beuzeboc, Philippe, additional, Flechon, Aude, additional, Cheneau, Caroline, additional, Martineau, Geraldine, additional, Borget, Isabelle, additional, and Fizazi, Karim, additional

Published
2019
Full Text
View/download PDF

40. ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC).

Author

Martineau, Geraldine, primary, Foulon, Stéphanie, additional, Baciarello, Giulia, additional, Joly, Florence, additional, Delva, Remy, additional, Barthelemy, Philippe, additional, Neuzillet, Yann, additional, Priou, Franck, additional, Hue, Anne Sophie, additional, and Fizazi, Karim, additional

Published
2019
Full Text
View/download PDF

42. A qualitative evaluation of the use of interventions to treat fatigue among cancer survivors: A healthcare provider's view.

Author

Martin, Elise, Zingarello, Anna, Di Meglio, Antonio, Baciarello, Giulia, Matias, Margarida, Charles, Cécile, Arvis, Johanna, Dumas, Agnès, Menvielle, Gwenn, and Vaz‐Luis, Ines

Subjects
ATTITUDE (Psychology), CROSS-sectional method, RESEARCH methodology, MEDICAL personnel, INTERVIEWING, CANCER patients, QUALITATIVE research, CANCER fatigue, QUALITY assurance, DESCRIPTIVE statistics, THEMATIC analysis
Abstract

Objective: Cancer‐related fatigue (CRF) is among the most common and distressing side effects of cancer treatment. Different types of interventions, including physical activity (PA), psychosocial and mind–body interventions, have been shown to reduce CRF. We aimed to explore HCPs' practices and barriers to refer patients towards interventions to reduce CRF. Methods: We performed a qualitative study using key informant interviews among a sample of 20 HCPs including medical, surgical and radiation oncologists, pain specialists, nurses, psychologists, psychiatrists and physiotherapists recruited from breast, prostate and colorectal cancer disease groups from a comprehensive cancer centre. Results: Most interviewees reported not to address CRF spontaneously during consultations. When the topic of CRF was brought up by patients, all interviewees acknowledged to recommend PA, whereas few would recommend psychosocial or mind–body interventions. Barriers to recommend interventions to manage CRF included: lack of knowledge about CRF and its treatment, lack of time and complexity of the referral due to their accessibility and cost. Conclusion: In a diverse sample of HCPs, most acknowledged not to address CRF proactively with their patients, but identified several actionable barriers. Specific training on screening and management of CRF and improving the referral network dedicated to interventions need to be implemented. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.

Author

Ross, Jeffrey S., Sokol, Ethan S., Moch, Holger, Mileshkin, Linda, Baciarello, Giulia, Losa, Ferran, Beringer, Andreas, Thomas, Marlene, Elvin, Julia A., Ngo, Nhu, Jin, Dexter X., and Krämer, Alwin

Subjects
BIOMARKERS, GENETIC mutation, DNA, SEQUENCE analysis, CANCER of unknown primary origin, RETROSPECTIVE studies, MANN Whitney U Test, MOLECULAR biology, GENOMICS, GENE expression profiling, DESCRIPTIVE statistics, DATA analysis software, IMMUNOTHERAPY
Abstract

Background: Carcinoma of unknown primary origin (CUP) accounts for 2%–5% of newly diagnosed advanced malignancies, with chemotherapy as the standard of care. CUPISCO (NCT03498521) is an ongoing randomized trial using comprehensive genomic profiling (CGP) to assign patients with CUP to targeted or immunotherapy treatment arms based on genomic profiling. We performed a retrospective analysis of CUP cases referred for CGP to determine how many were potentially eligible for enrollment into an experimental CUPISCO arm. Materials and Methods: Centrally reviewed adenocarcinoma and undifferentiated CUP specimens in the FoundationCore database were analyzed using the hybrid capture‐based FoundationOne CDx assay (mean coverage, >600×). Presence of genomic alterations, microsatellite instability (MSI), tumor mutational burden (TMB), genomic loss of heterozygosity (gLOH), and programmed death‐ligand 1 (PD‐L1) positivity were determined. Results: A total of 96 of 303 patients (31.7%) could be matched to an experimental CUPISCO arm. Key genomic alterations included ERBB2 (7.3%), PIK3CA (6.3%), NF1 (5.6%), NF2 (4.6%), BRAF (4.3%), IDH1 (3.3%), PTEN, FGFR2, EGFR (3.6% each), MET (4.3%), CDK6 (3.0%), FBXW7, CDK4 (2.3% each), IDH2, RET, ROS1, NTRK (1.0% each), and ALK (0.7%). Median TMB was 3.75 mutations per megabase of DNA; 34 patients (11.6%) had a TMB ≥16 mutations per megabase. Three patients (1%) had high MSI, and 42 (14%) displayed high PD‐L1 expression (tumor proportion score ≥50%). gLOH could be assessed in 199 of 303 specimens; 19.6% had a score of >16%. Conclusions: Thirty‐two percent of patients would have been eligible for targeted therapy in CUPISCO. Future studies, including additional biomarkers such as PD‐L1 positivity and gLOH, may identify a greater proportion potentially benefiting from CGP‐informed treatment. Clinical trial identification number. NCT03498521 Implications for Practice: The findings of this retrospective analysis of carcinoma of unknown primary origin (CUP) cases validate the experimental treatment arms being used in the CUPISCO study (NCT03498521), an ongoing randomized trial using comprehensive genomic profiling to assign patients with CUP to targeted or immunotherapy treatment arms based on the presence of pathogenic genomic alterations. The findings also suggest that future studies including additional biomarkers and treatment arms, such as programmed death‐ligand 1 positivity and genomic loss of heterozygosity, may identify a greater proportion of patients with CUP potentially benefiting from comprehensive genomic profiling‐informed treatment. This article focuses on the ability of comprehensive genomic profiling to identify potentially targetable genetic alterations in cancers of unknown primary, based on the inclusion criteria for the CUPISCO clinical trial and aiming for more effective therapeutic options for patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease‐19 Pandemic: A Survey of International Expertise Centers.

Author

Nappi, Lucia, Ottaviano, Margaret, Rescigno, Pasquale, Tortora, Marianna, Banna, Giuseppe L., Baciarello, Giulia, Basso, Umberto, Canil, Christina, Cavo, Alessia, Cossu Rocca, Maria, Czaykowski, Piotr, De Giorgi, Ugo, Garcia del Muro, Xavier, Di Napoli, Marilena, Fornarini, Giuseppe, Gietema, Jourik A., Heng, Daniel Y.C., Hotte, Sebastien J., Kollmannsberger, Christian, and Maruzzo, Marco

Subjects
EMERGENCY medicine, EPIDEMICS, SURVEYS, DISEASE management, DATA analysis software, DESCRIPTIVE statistics, GERMINOMA, COVID-19 pandemic
Abstract

Background: The coronavirus disease 2019 (COVID‐19) pandemic has become a public health emergency affecting frail populations, including patients with cancer. This poses the question of whether cancer treatments can be postponed or modified without compromising their efficacy, especially for highly curable cancers such as germ cell tumors (GCTs). Materials and Methods: To depict the state‐of‐the‐art management of GCTs during the COVID‐19 pandemic, a survey including 26 questions was circulated by e‐mail among the physicians belonging to three cooperative groups: (a) Italian Germ Cell Cancer Group; (b) European Reference Network–Rare Adult Solid Cancers, Domain G3 (rare male genitourinary cancers); and (c) Genitourinary Medical Oncologists of Canada. Percentages of agreement between Italian respondents (I) versus Canadian respondents (C), I versus European respondents (E), and E versus C were compared by using Fisher's exact tests for dichotomous answers and chi square test for trends for the questions with three or more options. Results: Fifty‐three GCT experts responded to the survey: 20 Italian, 6 in other European countries, and 27 from Canada. Telemedicine was broadly used; there was high consensus to interrupt chemotherapy in COVID‐19–positive patients (I = 75%, C = 55%, and E = 83.3%) and for use of granulocyte colony‐stimulating factor primary prophylaxis for neutropenia (I = 65%, C = 62.9%, and E = 50%). The main differences emerged regarding the management of stage I and stage IIA disease, likely because of cultural and geographical differences. Conclusion: Our study highlights the common efforts of GCT experts in Europe and Canada to maintain high standards of treatment for patients with GCT with few changes in their management during the COVID‐19 pandemic. Implications for Practice: Despite the chaos, disruptions, and fears fomented by the COVID‐19 illness, oncology care teams in Italy, other European countries, and Canada are delivering the enormous promise of curative management strategies for patients with testicular cancer and other germ cell tumors. At the same time, these teams are applying safe and innovative solutions and sharing best practices to minimize frequency and intensity of patient contacts with thinly stretched health care capacity. This article focuses on state‐of‐the‐art management of testicular germ cell tumors during the COVID‐19 pandemic, highlighting different approaches based on the pandemic experience in each individual country. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

48. ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC).

Author

Martineau, Geraldine, primary, Foulon, Stéphanie, additional, Eymard, Jean-Christophe, additional, Loriot, Yohann, additional, Baciarello, Giulia, additional, Berdah, Jean Francois, additional, Helissey, Carole, additional, Lavaud, Pernelle, additional, Joly, Florence, additional, Zaghdoud, Nadia, additional, Hue, Anne Sophie, additional, and Fizazi, Karim, additional

Published
2018
Full Text
View/download PDF

50. Activity of third line (3L) therapy in patients with metastatic non-clear-cell renal cell carcinoma (mnccRCC).

Author

Guida, Annalisa, primary, Le Teuff, Gwénaël, additional, Colomba, Emeline, additional, Silva, Carolina Alveosta, additional, Salviat, Flore, additional, Baciarello, Giulia, additional, Derosa, Lisa, additional, Loriot, Yohann, additional, Fizazi, Karim, additional, Di Palma, Mario, additional, Massard, Christophe, additional, Escudier, Bernard, additional, and Albiges, Laurence, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results